Kolon TissueGene Decides on 47.8 Billion KRW Paid-in Capital Increase
Kolon TissueGene announced on the 23rd that it has decided to conduct a paid-in capital increase worth 47.8 billion KRW to secure operating funds.
The company will issue 762,350 common shares at 62,460 KRW per share through a third-party allotment. The third-party allotment target is Kolon Co., Ltd., the largest shareholder.
Hot Picks Today
!["Tired of Sidecars"... Retail Investors Flock to 'Monthly Income ETFs' [Practical Asset Management]](https://cwcontent.asiae.co.kr/asiaresize/93/2026072908435061882_1785282231.jpg)
"Tired of Sidecars"... Retail Investors Flock to 'Monthly Income ETFs' [Practical Asset Management]
- "What About Retail Investors?... Tens of Trillions Lost as Leveraged ETF Bets Backfire"
- [Breaking] Jung Jaeheon: "The AI Era Is Global Competition...AIDC Alliance Marks the Beginning of Solidarity"
- A Security Guard in China Who Was Told "You'll End Up Like That If You Don't Study" Changes His Life Through Determination
- Brazilian Actress Picks Her "Favorite Korean Cosmetic"... K-Beauty Penetrates the World’s Third-Largest Market [K-Beauty’s Surge]①
Regarding the selection process, the company stated, "The allocation was made considering the investor's intention and payment capability to achieve management objectives and raise funds."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
![Speaker Jo Jung-sik's Remarks on Presidential Re-Election Backfire, Fueling Constitutional Amendment Controversy [Politics in Focus]](https://cwcontent.asiae.co.kr/asiaresize/307/2026072913044262565_1785297882.jpg)
